Aug. 14 : Sigma-Aldrich , a leading $1.8 billion Life Science and High Technology company, has signed a national distribution agreement with CellPath, a leading distributor of healthcare products, to serve the healthcare market in the UK.
Aug. 14 : At the Board of Directors meeting held today, the Directors declared a quarterly cash dividend of $.115 per share. The dividend is payable on September 14, 2007 to shareholders of record on August 31, 2007.
Sigma-Aldrich Corporation , a leading Life Science and High Technology company with 2006 revenues of $1.8 billion, and Sangamo BioSciences, Inc. ,
SAFC, a member of the Sigma-Aldrich Group, announced today that it has completed the initial phase of a two-stage expansion at its SAFC Pharmorphix(TM) research facility in Cambridge, U.K., for its SAFC Pharma business. Completion of a 2,500 sq.
Jan. 30 : Sigma-Aldrich , a leading $1.7 billion Life Science and High Technology Company, is pleased to announce it has launched Protease Finder, a novel Internet-based program expected to accelerate customers’ success
Jan. 25 : Sigma-Aldrich , a leading $1.7 billion Life Science Company and member of The RNAi Consortium (TRC), proudly welcomes the Vanderbilt-Ingram Cancer Center and the University of Michigan to the RNAi Partnership Program.
Jan. 23 : Sigma-Aldrich , a leading $1.7 billion Life Science and High Technology company, is pleased to launch the GenomePlex Tissue Whole Genome Amplification (WGA) Kit. This kit is the latest addition to the GenomePlex product line and includes all of the reagents needed for extraction and whole genome amplification from as little [...]
Jan 16 : SAFC, a member of the Sigma- Aldrich Group , announced today that its SAFC Pharma business segment has been appointed by Affichem, a French biotechnology company, to provide chemical development services relating to Dendrogenine A, a potential cancer treatment.
Jan 03 : Sigma-Aldrich , a leading $1.7 billion Life Science and High Technology company, announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology.
Sigma-Aldrich , a $1.7 billion Life Science and High Technology company, announced the release of the Universal Proteomics Standard during the HUPO Protein Test Sample Standards/NIST Workshop, an educational session prior to the HUPO 5th Annual World Congress. The standard, a complex mixture of 48 human proteins,